Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 12/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 9/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13819538 | 0.89 | ALOX5 (0.41) | PKMKDM4EALDH1A1GAAKMT2A | |
| SCHEMBL6716285 | 0.87 | CNR2 (0.43) | KDM4EKMT2ACNR2CNR1CYP3A4 | |
| SCHEMBL27602008 | 0.83 | CNR2 (0.48) | KMT2ACNR2CNR1CYP1A2CYP3A4 | |
| SCHEMBL20929943 | 0.82 | CNR2 (0.61) | CNR2CNR1 | |
| SCHEMBL20930037 | 0.81 | GAA (0.46) | PKMKDM4EALDH1A1GAAKMT2A | |
| SCHEMBL5430441 | 0.81 | CNR2 (0.63) | CNR2CNR1 | |
| SCHEMBL3705499 | 0.80 | CNR2 (0.44) | ALDH1A1KMT2ACNR2CNR1CA1 | |
| SCHEMBL13819539 | 0.80 | CNR2 (0.40) | PKMKDM4EALDH1A1GAAKMT2A | |
| SCHEMBL3693693 | 0.79 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL3694612 | 0.78 | CNR2 (0.42) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173867-B2 | Treatment of immune dysregulation using cannabinoid derivatives | IMMUGEN PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173867-B2 | Treatment of immune dysregulation using cannabinoid derivatives | IMMUGEN PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | IMMUGEN PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | IMMUGEN PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| US-8586767-B2 | Method for treatment of HIV and diseases of immune dysregulation | TRAVIS CRAIG RICK (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586767-B2 | Method for treatment of HIV and diseases of immune dysregulation | TRAVIS CRAIG RICK (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | TRAVIS CRAIG RICK (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | TRAVIS CRAIG RICK (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120122917-A1 | Method For Treatment Of HIV And Diseases Of Immune Dysregulation | TRAVIS CRAIG RICK (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122917-A1 | Method For Treatment Of HIV And Diseases Of Immune Dysregulation | TRAVIS CRAIG RICK (US) | 2012-05-17 | — | — | US | disclosed |
| US-6541510-B2 | Cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus, especially HIV. | IMMUGEN PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | disclosed |
| WO-2002026224-A9 | METHODS AND COMPOUNDS FOR INHIBITING EICOSANOID METABOLISM AND PLATELET AGGREGATION | IMMUGEN PHARMACEUTICALS INC (US) | 2003-02-20 | — | — | WO | disclosed |
| US-20020137802-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | IMMUGEN PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020068738-A1 | Antiviral methods and compounds | IMMUGEN PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002026728-A2 | ANTIVIRAL METHODS AND COMPOUNDS | IMMUGEN PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026224-A2 | METHODS AND COMPOUNDS FOR INHIBITING EICOSANOID METABOLISM AND PLATELET AGGREGATION | IMMUGEN PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-20020037923-A1 | Resorcinolic compounds | IMMUGEN PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1189603-A2 | TREATMENT OF IMMUNE DISEASES LIKE HIV DISEASE AND NEOPLASTIC DISORDERS | Immugen Pharmaceuticals, Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6274635-B1 | ANTITUMOR AGENTS | IMMUGEN PHARMACEUTICALS INC. | 2001-08-14 | — | — | US | disclosed |
| WO-2000056303-A2 | TREATMENT OF IMMUNE DISEASES | IMMUGEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | CNR2, CNR1, GPR18 | PKM 4037/4885KDM4E 789/4885ALDH1A1 3563/4885 |
| US-20020037923-A1 | Resorcinolic compounds | VHL, HRAS, CYP46A1 | PKM 3878/4885KDM4E 4081/4885ALDH1A1 1839/4885 |
| US-20020068738-A1 | Antiviral methods and compounds | MAVS, CNR1, ZC3HAV1 | PKM 4251/4885KDM4E 1875/4885ALDH1A1 3995/4885 |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | CNR2, CNR1, GPR18 | PKM 4037/4885KDM4E 789/4885ALDH1A1 3563/4885 |
| US-20120122917-A1 | Method For Treatment Of HIV And Diseases Of Immune Dysregulation | CNR2, CNR1, ICOS | PKM 3249/4885KDM4E 479/4885ALDH1A1 3303/4885 |
| US-20020137802-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | PTGS1, PTGIS, PTGES | PKM 3223/4885KDM4E 4027/4885ALDH1A1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.